“…The high cost of the disease demands that public and private health systems investigate new treatments, intervention programs (Ejtahed et al, 2012;König, Kookhan, Schaffner, Deibert, & Berg, 2014;Shen, Obin, & Zhao., 2013;Costa & Longo, 2014) and drugs capable to improve the patients' quality of life. In living beings, the α-amylases are enzymes that catalyze the hydrolysis of polysaccharides, such as starch and glycogen, to yield glucose and maltose (Wang et al, 2008). However, some organic compounds, among them acarbose, may inhibit the activity of these enzymes (Geng & Bai, 2008;Ritz et al, 2012) and thus prevent or attenuate hyperglycemic peaks (Coniff, Shapiro, Seaton, & Bray, 1995;Pereira et al, 2011;Scheen, Magalhaes, Salvatore, & Lefebvre, 1994;Sybuia, Guilhermetti, Mangolim, Bazotte, & Matioli, 2014-2015Wong & Jenkins, 2007).…”